Een vrouw met kort lichtbruin haar en een bril, draagt een grijze coltrui, donkere blazer en parelketting, glimlacht op een wazige achtergrond in de hal van een advocatenkantoor.

Courtenay C. Brinckerhoff

Partner

Courtenay C. Brinckerhoff

Partner

Courtenay Brinckerhoff is an intellectual property lawyer, assisting international clients with all aspects of obtaining, defending, evaluating, licensing, and enforcing patents; and conducting freedom-to-operate and due diligence investigations. She is a partner and vice chair of the firm’s Intellectual Property Department, as well as the editor and primary author for Foley’s PharmaPatentsBlog.com, where she analyzes evolving patent office practices and precedential court decisions on emerging legal issues.

For more than 25 years, Courtenay has represented clients in diverse industries before the U.S. Patent Office, the Patent Trial and Appeal Board, and the U.S. Court of Appeals for the Federal Circuit. She has successfully represented clients in complex patent matters, including four-party interference, Inter partes Reexaminations, Inter partes Reviews, and ANDA litigation.

Courtenay works with clients across the chemical and biotechnology industries, including on innovations for pharmaceuticals and drug-device products, human and animal food products and nutraceuticals, and industrial technologies. Clients trust Courtenay to secure critical intellectual patent rights, including patents intended for listing in the Orange Book or eligible for listing in the Purple Book.

She has particular experience with transdermal pharmaceutical products (patches, gels, and liquids), oral dosage forms (including controlled/extended-release formulations), enzyme-based technologies, microbial technologies, diagnostic and therapeutic antibodies, active and passive immunization therapies, and personalized medicine, as well as with industrial films, carbon nanotube technologies, biofuels, and carbon capture technologies.

Courtenay has served as vice chair of the firm’s Chemical, Biotechnology & Pharmaceutical Practice and is an active member of the firm’s PTAB Trials Practice and Life Sciences Industry Team.

Prior to joining Foley as an associate, Courtenay clerked for the Honorable Alvin Anthony Schall on the U.S. Court of Appeals for the Federal Circuit. Prior to her clerkship, she worked at Foley as a patent agent and law clerk.

Prijzen en erkenning

  • Stand-out Lawyer, Thomson Reuters (2025)
  • The Best Lawyers in America©, Patent Law (2021-2024) and Biotechnology and Life Sciences Practice (2023-2024)
  • IP Distinguished Alumni Award from George Mason University Antonin Scalia Law School (April 2017)
  • JD Supra Readers’ Choice Top Author (2017-2021) in the categories of pharmaceutical industry and patents for her work on the PharmaPatents blog
  • IAM Patent 1000 – The World’s Leading Patent Practitioners, patent prosecution (2014-2016, 2020-2021, 2024-2025)
  • Top Women in IP, Managing IP (2015)
  • IP Star, Managing IP (2015)

Gedachtegoed

Courtenay writes and speaks on topics important to clients in chemical, biotechnological, pharmaceutical, food, and personalized medicine industries. She has been an invited speaker at the AIPLA Annual Meeting, the FDLI Annual Meeting, the Intellectual Property Owner’s Association annual meeting, the PTAB Bar Association annual meeting, and the annual Advanced Patent Law Institute presented by the University of Texas School of Law, the United States Patent and Trademark Office, and George Mason University Antonin Scalia Law School.

Courtenay currently serves as a Vice Chair of the Intellectual Property Owner’s Association Patent Office Practice Committee and as a Vice Chair of the Appeals to the PTAB Committee of the PTAB Bar Association.

Courtenay has been following U.S. patent reform since its inception, and she and other Foley colleagues co-authored the treatise, America Invents Act: Law & Analysis (Wolters Kluwer 2012). The interface between patent law and FDA law is another area of interest, and she has written and spoken on issues including patent term extension, the scope of the Hatch-Waxman “safe harbor,” the ANDA litigation framework, and the biosimilars BPCIA framework.

 

24 oktober 2025 PharmaPatents

Handel snel voor een (bijna) gratis versneld onderzoek

Het USPTO heeft een nieuw proefprogramma aangekondigd om de achterstand in onbehandelde patentaanvragen efficiënt weg te werken. De...
21 oktober 2025 PTAB Proefinzichten

USPTO-directeur neemt controle over IPR- en PGR-instellingsbesluiten

In what some are perceiving as the second blow of a one-two punch against patent trial proceedings conducted at the U.S. Patent and...
16 oktober 2025 Geschillen IE Actueel

USPTO doet voorstel voor regelgeving over discretionaire afwijzingen van IPR-procedures

In het eerste voorstel voor regelgeving onder directeur Squires stelt het USPTO voor om de praktijkregels met betrekking tot...
9 oktober 2025 PharmaPatents

Helpt u het USPTO bij het testen van door AI gegenereerde prior art?

One of the goals of the new Director of the United States Patent and Trademark Office (USPTO) is to improve patent examination efficiency...
4 september 2025 PharmaPatents

Federal Circuit sceptisch over vervolgingsuitstel

In de zaak Google v. Sonos heeft de Federal Circuit de argumenten dat het litigieuze octrooi niet-afdwingbaar was door uitstel op basis van een...
5 juni 2025 Onderscheidingen

IAM erkent Foley-advocaten en -rechtsgebieden in editie 2025 van IAM Patent 1000: The World's Leading Patent Practitioners

Zeventien advocaten en vijf rechtsgebieden van Foley & Lardner LLP zijn opgenomen in de 2025-editie van IAM Patent 1000: The World's Leading Patent Practitioners.